Your employer appreciates your treatment !

Thursday, 24 November 2011 17:43

Research news

The effect of adalimumab upon work productivity

American researchers have recently collected data from 4 studies (ACCESS, CARE, CHOICE and EXTEND) concerning the work productivity of persons with mild to severe CD treated with adalimumab.

1,202 employees with CD were followed for a 20-week period. Questionnaires on productivity at work and impairment of activity (absence, presence and total work productivity impairment (TWPI) ) were analyzed.

Metanalyses enabled an evaluation of the  accumulated reduction in impairment of work productivity over a one-year period thanks to this treatment. Evaluation of the economy in indirect costs of patients during the year following the start of adalimumab was calculated using an annual average salary ($44,101).

The reduction in the absence rate generated $3,856 per patient, while the reduction  in the   TWPI generated $10,964.

In patients with mild to severe CD, use of adalimumab thus led to significant improvement both clinically and in terms of work productivity, with substantial savings in indirect costs.

 

References

Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: A meta-analysis
DG Binion, E Louis, B Oldenburg, P Mulani, AG Bensimon, M Yang, J Chao